COVID-19 vaccine effectiveness
(Randomized evidence)

If you want to see all comparisons, please click here

Sinopharm-Beijng-HB02 COVID-19 Vaccine vs Placebo

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots
(last update: 2021-06-04)

Evidence profile
2021-06-11

Summary of findings
2021-06-11

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04510207, ChiCTR2000034780
Sinopharm - China National Biotec Group Company Limited
Al Kaabi N, JAMA, 2021

Full text
Commentary
Commentary
Inactivated virus

WIV04

HBO2

Placebo

RCT
Phase 3
Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain N=40411
Some concerns
Details

Full description

ChiCTR2000032459
Beijing Institute of Biological Products/Sinopharm
Xia S, Lancet Infect Dis, 2020

Full text
Commentary
Inactivated virus

BBIBP-CorV 8mcg once

BBIBP-CorV 4mcg D0/14

BBIBP-CorV 4mcg D0/21

BBIBP-CorV 4mcg D0/28

Placebo

RCT
Phase 2
Healthy SARS-CoV-2 serology negative adults 18-59 years old and ≥60 years old in a single centre in China N=448
Some concerns
Details

Full description